6-mercapto-2-oxo-1,2,3,4-tetrahydroquinoline | 66657-43-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 6-mercapto-2-oxo-1,2,3,4-tetrahydroquinoline
• 英文别名: 6-mercapto-3,4-dihydroquinolin-2(1H)-one；6-mercapto-1,2,3,4-tetrahydroquinolin-2-one；6-mercapto-3,4-dihydrocarbostyril；6-sulfanyl-3,4-dihydro-1H-quinolin-2-one
• CAS: 66657-43-0
• 化学式: C₉H₉NOS
• 分子量: 179.243
• InChiKey: BXDVDIDSJBMUMU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  30.1
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  6-mercapto-2-oxo-1,2,3,4-tetrahydroquinoline 在 sodium hydroxide 、 双氧水 、 溶剂黄146 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 4.0h， 生成 6-(3-ethoxycarbonylpropylsulfonyl)-2-oxo-1,2,3,4-tetrahydroquinoline
  参考文献：
  名称：

  2-氧代喹啉衍生物作为血小板聚集抑制剂的研究。I.4-（2-氧代-1,2,3,4-四氢-6-喹啉基氧基）丁酸酯和相关化合物。

  摘要：

  合成并测试了许多烷基4-(2-氧代-1, 2, 3, 4-四氢-6-喹啉氧基)丁酸酯及相关化合物对体外血小板聚集的抑制活性。其中，乙基4-(2-氧代-1, 2, 3, 4-四氢-6-喹啉氧基)丁酸酯显示出最强的抑制活性。讨论了构效关系。

  DOI：

  10.1248/cpb.31.798
• 作为产物：
  描述：

  1,2,3,4-四氢-2-氧代-6-喹啉磺酰氯 在 硫酸 、 锌 作用下， 以 水 为溶剂， 反应 5.0h， 以68.6%的产率得到6-mercapto-2-oxo-1,2,3,4-tetrahydroquinoline
  参考文献：
  名称：

  2-氧代喹啉衍生物作为血小板聚集抑制剂的研究。I.4-（2-氧代-1,2,3,4-四氢-6-喹啉基氧基）丁酸酯和相关化合物。

  摘要：

  合成并测试了许多烷基4-(2-氧代-1, 2, 3, 4-四氢-6-喹啉氧基)丁酸酯及相关化合物对体外血小板聚集的抑制活性。其中，乙基4-(2-氧代-1, 2, 3, 4-四氢-6-喹啉氧基)丁酸酯显示出最强的抑制活性。讨论了构效关系。

  DOI：

  10.1248/cpb.31.798

文献信息

• Carbostyril derivatives and salts thereof and pharmaceutical composition
  申请人：Otsuka Pharmaceutical Co., Ltd.

  公开号：US05008274A1

  公开（公告）日：1991-04-16

  A carbostyril derivative or pharmaceutically acceptable salt thereof represented by the following general formula: ##STR1## wherein Z, A, XN, R, R.sup.1, and R.sup.2 are as defined in the specification. These carbostyril derivatives are useful in pharmaceutical compositions for inhibiting adhesion of thrombocytes.

  下列一般式所示的碳基喹啉衍生物或其制药可接受的盐：##STR1## 其中Z，A，XN，R，R.sup.1和R.sup.2如规范中所定义。这些碳基喹啉衍生物在制药组合物中用于抑制血小板粘附。
• Carbostyril derivatives and salts thereof and pharmaceutical
  申请人：Otsuka Pharmaceutical Co. Ltd.

  公开号：US05434164A1

  公开（公告）日：1995-07-18

  Carbostyril derivatives and salts thereof represented by the general formula (1a), including some known compounds, possess activities for inhibiting adhesion of thrombocytes. ##STR1## Z, A, X, R, R.sup.1 and R.sup.2 are defined in the specification. Some carbostyril derivatives having chemical structural formulas similar to those of carbostyril derivatives and salts thereof represented by the general formula (1a) have been known in prior art references, however the above-mentioned pharmacological activities have not been known to the present date.

  通式（1a）所表示的羧基苯基咪唑衍生物及其盐，包括一些已知化合物，具有抑制血小板粘附活性。其中，Z、A、X、R、R.sup.1和R.sup.2在说明书中有定义。先前的文献中已知一些具有与通式（1a）所表示的羧基苯基咪唑衍生物及其盐相似的化学结构式的羧基苯基咪唑衍生物，但上述药理活性直到现在才被发现。
• Ether derivatives having 5-lipoxygenase inhibitory activity
  申请人：Zeneca Limited

  公开号：US05478842A1

  公开（公告）日：1995-12-26

  The invention concerns ether derivatives of the formula I Q.sup.1 --X--Ar--Q.sup.2 I wherein Q.sup.1 is an optionally substituted 9-, 10- or 11-membered bicyclic heterocyclic moiety containing one or two nitrogen heteroatoms and optionally containing a further heteroatom selected from nitrogen, oxygen and sulphur; X is oxy, thio, sulphinyl or sulphonyl; Ar is optionally substituted phenylene, pyridinediyl, pyrimidinediyl, thiophenediyl, furandiyl, thiazolediyl, oxazoiediyl, thiadiazoiediyl or oxadiazolediyl; and Q.sup.2 is selected from the groups of the formulae II and III: ##STR1## wherein R.sup.1 is hydrogen, (2-5C)alkanoyl or optionally substituted benzoyl; R.sup.2 is (1-4C)alkyl; and R.sup.3 is hydrogen or (1-4C)alkyl; or R.sup.2 and R.sup.3 are linked to form a methylene, vinylene, ethylene or trimethylene group; or a pharmaceutically-acceptable salt thereof; processes for their preparation; pharmaceutical compositions containing them and their use as 5-lipoxygenase inhibitors.

  本发明涉及公式I Q.sup.1--X--Ar--Q.sup.2 I的醚衍生物，其中Q.sup.1是一种可选取代的9、10或11元杂环螺环烷基，其中包含一或两个氮杂原子，并可选取自氮、氧和硫的进一步杂原子；X是氧、硫、亚磺酰基或磺酰基；Ar是可选取代的苯基、吡啶基、嘧啶基、噻吩基、呋喃基、噻唑基、噁唑基、噻二唑基或噁二唑基；Q.sup.2选自公式II和III的基团：##STR1##其中R.sup.1是氢、(2-5C)脂肪酰基或可选取代的苯甲酰基；R.sup.2是(1-4C)烷基；R.sup.3是氢或(1-4C)烷基；或R.sup.2和R.sup.3连接形成亚甲基、乙烯基、乙烷基或三亚甲基基团；或其药学上可接受的盐；制备它们的方法；包含它们的制药组合物以及它们作为5-脂氧合酶抑制剂的用途。
• Carbostyril derivatives, process for preparing them, pharmaceutical composition, and use
  申请人：OTSUKA PHARMACEUTICAL CO., LTD.

  公开号：EP0240015A2

  公开（公告）日：1987-10-07

  Carbostyril derivatives and salts thereof represented by the general formula (1), including some known compounds, possess activities for inhibiting adhesion of thrombocytes. Some carbostyril derivatives having chemical structural formulas similar to those of carbostyril derivatives and salts thereof represented by the general formula (1) have been known in the prior art references, however above-mentioned pharmacological activities have not been known yet up to the date. Processes for preparing carbostyril derivatives offormu- la (1), a pharmaceutical composition containing them, or a salt thereof, as active ingredient, and their use in the preparation of a medicament for inhibiting adhesion of thrombocytes are also disclosed.

  通式(1)代表的羧基吡啶衍生物及其盐类，包括一些已知化合物，具有抑制血小板粘附的活性。 一些羧基吡啶衍生物的化学结构式与通式(1)代表的羧基吡啶衍生物及其盐类相似，在现有技术参考文献中已为人所知，但上述药理活性至今尚未为人所知。 本发明还公开了制备通式(1)代表的羧基吡啶衍生物、含有它们或其盐类作为活性成分的药物组合物的工艺，以及它们在制备抑制血小板粘附的药物中的用途。
• Optimization of diaryl amine derivatives as kinesin spindle protein inhibitors
  作者：Tomoki Takeuchi、Shinya Oishi、Masato Kaneda、Ryosuke Misu、Hiroaki Ohno、Jun-ichi Sawada、Akira Asai、Shinya Nakamura、Isao Nakanishi、Nobutaka Fujii

  DOI：10.1016/j.bmc.2014.04.008

  日期：2014.6

  Structure-activity relationship studies of diaryl amine-type KSP inhibitors were carried out. Diaryl amine derivatives with a pyridine ring or urea group were less active when compared with the parent carboline and carbazole derivatives. Optimization studies of a lactam-fused diphenylamine-type KSP inhibitor revealed that the aniline NH group and 3-CF3 phenyl group were indispensable for potent KSP inhibition. Modification with a seven-membered lactam-fused phenyl group and a 4-(trifluoromethyl)pyridin-2-yl group improved aqueous solubility while maintaining potent KSP inhibitory activity. From these studies, we identified novel diaryl amine-type KSP inhibitors with a favorable balance of potency and solubility. (C) 2014 Elsevier Ltd. All rights reserved.